WO1994021650A1 - Boronic acid and ester inhibitors of thrombin - Google Patents
Boronic acid and ester inhibitors of thrombin Download PDFInfo
- Publication number
- WO1994021650A1 WO1994021650A1 PCT/US1994/002965 US9402965W WO9421650A1 WO 1994021650 A1 WO1994021650 A1 WO 1994021650A1 US 9402965 W US9402965 W US 9402965W WO 9421650 A1 WO9421650 A1 WO 9421650A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloride
- boroarginine
- pinanediol
- phenyl
- borothioarginine
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 16
- 108090000190 Thrombin Proteins 0.000 title description 17
- 229960004072 thrombin Drugs 0.000 title description 17
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 title description 5
- 150000002148 esters Chemical class 0.000 title description 2
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 230000001810 trypsinlike Effects 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 232
- 229910052739 hydrogen Inorganic materials 0.000 claims description 113
- 150000001875 compounds Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 24
- -1 cyclic boron ester Chemical class 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 10
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 10
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 10
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 6
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 239000004305 biphenyl Chemical group 0.000 claims description 3
- 235000010290 biphenyl Nutrition 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 claims description 2
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 abstract description 4
- MOILFCKRQFQVFS-OORONAJNSA-N (1s,3r,4s,5s)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical compound C1[C@H]2C(C)(C)[C@@H]1C[C@@H](O)[C@]2(O)C MOILFCKRQFQVFS-OORONAJNSA-N 0.000 description 165
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 54
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 54
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 11
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 10
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- 229940122388 Thrombin inhibitor Drugs 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003868 thrombin inhibitor Substances 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 238000010640 amide synthesis reaction Methods 0.000 description 6
- 150000001540 azides Chemical class 0.000 description 6
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- GSYSFVSGPABNNL-UHFFFAOYSA-N methyl 2-dimethoxyphosphoryl-2-(phenylmethoxycarbonylamino)acetate Chemical group COC(=O)C(P(=O)(OC)OC)NC(=O)OCC1=CC=CC=C1 GSYSFVSGPABNNL-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- KUNBXXXSURELJF-INIZCTEOSA-N [(1R)-1-aminobutyl]-(4-phenylbenzoyl)oxyborinic acid Chemical compound C1=CC(C(=O)OB(O)[C@@H](N)CCC)=CC=C1C1=CC=CC=C1 KUNBXXXSURELJF-INIZCTEOSA-N 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- AOPRFYAPABFRPU-UHFFFAOYSA-N amino(imino)methanesulfonic acid Chemical compound NC(=N)S(O)(=O)=O AOPRFYAPABFRPU-UHFFFAOYSA-N 0.000 description 3
- 230000002965 anti-thrombogenic effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 229960003766 thrombin (human) Drugs 0.000 description 3
- 229940019333 vitamin k antagonists Drugs 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 2
- 108090000935 Antithrombin III Proteins 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 102100027612 Kallikrein-11 Human genes 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 241001264631 Theonella sp. Species 0.000 description 2
- 101710152431 Trypsin-like protease Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001994 activation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 229960005348 antithrombin iii Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 125000005620 boronic acid group Chemical class 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 150000002009 diols Chemical group 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- PWWSSIYVTQUJQQ-UHFFFAOYSA-N distearyl thiodipropionate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCCCCCCCC PWWSSIYVTQUJQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- MOILFCKRQFQVFS-BDNRQGISSA-N (1r,3s,4r,5r)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol Chemical class C1[C@@H]2C(C)(C)[C@H]1C[C@H](O)[C@@]2(O)C MOILFCKRQFQVFS-BDNRQGISSA-N 0.000 description 1
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- WNCIWSMKRPFIJY-BTAJCFKJSA-N (2s)-2-[[(2s,3s)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[(2,5-dihydroxybenzoyl)amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoyl]amino]butanoic acid Chemical compound CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)C1=CC(O)=CC=C1O WNCIWSMKRPFIJY-BTAJCFKJSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- JHDMMNYIVVWNOF-UHFFFAOYSA-N 1,2-dicyclohexylethane-1,1-diol Chemical compound C1CCCCC1C(O)(O)CC1CCCCC1 JHDMMNYIVVWNOF-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- AIILPCNZWBMJTL-UHFFFAOYSA-N 1-aminobutylboronic acid Chemical compound CCCC(N)B(O)O AIILPCNZWBMJTL-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- OBGFNGZXMSFPAR-UHFFFAOYSA-N 2,5-dimethylhexane-3,3-diol Chemical compound CC(C)CC(O)(O)C(C)C OBGFNGZXMSFPAR-UHFFFAOYSA-N 0.000 description 1
- IMGMUZYPDHRPGZ-UHFFFAOYSA-N 2-(3-methoxypropylamino)acetic acid Chemical compound COCCCNCC(O)=O IMGMUZYPDHRPGZ-UHFFFAOYSA-N 0.000 description 1
- AHLFJIALFLSDAQ-UHFFFAOYSA-N 2-(pentylazaniumyl)acetate Chemical compound CCCCCNCC(O)=O AHLFJIALFLSDAQ-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- KFJCXIOVAGJCKB-UHFFFAOYSA-N 4-(3-amino-1h-indazol-5-yl)-n-tert-butylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NC(C)(C)C)=CC=C1C1=CC=C(NN=C2N)C2=C1 KFJCXIOVAGJCKB-UHFFFAOYSA-N 0.000 description 1
- NFZKAAWOLQALCJ-UHFFFAOYSA-N 4-(hydrazinylmethylideneamino)benzoic acid Chemical class NNC=NC1=CC=C(C(O)=O)C=C1 NFZKAAWOLQALCJ-UHFFFAOYSA-N 0.000 description 1
- JPVUWCPKMYXOKW-UHFFFAOYSA-N 4-phenylbenzoyl chloride Chemical compound C1=CC(C(=O)Cl)=CC=C1C1=CC=CC=C1 JPVUWCPKMYXOKW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 241001480736 Amblyomma hebraeum Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003274 Arthritis viral Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- PXPNSQMWVPLERM-UHFFFAOYSA-N CC(Oc1ccccc11)=CC1=O Chemical compound CC(Oc1ccccc11)=CC1=O PXPNSQMWVPLERM-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- CDWXSPKJKIUEQF-UHFFFAOYSA-N Cyclotheonamide A Natural products N1C(=O)C(CC=2C=CC=CC=2)NC(=O)C(=O)C(CCCN=C(N)N)NC(=O)C2CCCN2C(=O)C(NC=O)CNC(=O)C=CC1CC1=CC=C(O)C=C1 CDWXSPKJKIUEQF-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006219 Matteson homologation reaction Methods 0.000 description 1
- WNCIWSMKRPFIJY-UHFFFAOYSA-N Nazumamide A Natural products CCC(C(O)=O)NC(=O)C(C(C)CC)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1=CC(O)=CC=C1O WNCIWSMKRPFIJY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 102100034869 Plasma kallikrein Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910007161 Si(CH3)3 Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HUZKCJIICFRRDY-BYPYZUCNSA-N [(1R)-1-amino-4-bromobutyl]boronic acid Chemical compound OB(O)[C@@H](N)CCCBr HUZKCJIICFRRDY-BYPYZUCNSA-N 0.000 description 1
- WLXVBYMDLZBZOQ-INIZCTEOSA-N [(1R)-4-azido-1-[(4-phenylbenzoyl)amino]butyl]boronic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC[N-][N+]#N)B(O)O)=CC=C1C1=CC=CC=C1 WLXVBYMDLZBZOQ-INIZCTEOSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010090124 cyclotheonamide A Proteins 0.000 description 1
- CDWXSPKJKIUEQF-AOLOITIXSA-N cyclotheonamide a Chemical compound C([C@@H]1\C=C/C(=O)NC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N1)=O)CCCNC(=N)N)NC=O)C1=CC=C(O)C=C1 CDWXSPKJKIUEQF-AOLOITIXSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- FUGIIBWTNARRSF-UHFFFAOYSA-N decane-5,6-diol Chemical compound CCCCC(O)C(O)CCCC FUGIIBWTNARRSF-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000006624 extrinsic pathway Effects 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- VBZWSGALLODQNC-UHFFFAOYSA-N hexafluoroacetone Chemical compound FC(F)(F)C(=O)C(F)(F)F VBZWSGALLODQNC-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- IJTLXOBSKIIETJ-UHFFFAOYSA-N n-[3-(2-amino-1,4,5,6-tetrahydropyrimidin-5-yl)-1-(4-methylpiperidin-1-yl)-1-oxopropan-2-yl]-5-(dimethylamino)naphthalene-1-sulfonamide;dihydrochloride Chemical compound Cl.Cl.C1CC(C)CCN1C(=O)C(NS(=O)(=O)C=1C2=CC=CC(=C2C=CC=1)N(C)C)CC1CNC(=N)NC1 IJTLXOBSKIIETJ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010068110 nazumamide A Proteins 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
- 230000034365 zymogen activation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- This invention relates to the discovery of new boronic acid derivatives which are inhibitors of
- thrombin and pharmaceutical compositions thereof.
- Hemostasis is the normal physiological process in which bleeding from an injured blood vessel is arrested. It is a dynamic and complex process in which thrombin plays a key role. Blood coagulation may occur through either of two cascades of zymogen activations, the extrinsic and intrinsic pathways of the coagulation cascade. The last protease in each pathway is thrombin, which acts to hydrolyze four small peptides (two FpA and two FpB) from each molecule of fibrinogen, thus
- the linear fibrin polymers may be cross-linked by factor Xllla, which is itself activated by thrombin.
- thrombin is a potent activator of platelets, upon which it acts at specific receptors. Thrombin activation of platelets leads to aggregation of the cells and secretion of additional factors that further accelerate the creation of a hemostatic plug. Thrombin also potentiates its own production by the activation of factors V and VIII (see Hemker and Beguin in: Jolles, et. al., "Biology and Pathology of Platelet Vessel Wall Interactions," pp.
- Thrombosis may be regarded as the pathological condition wherein improper activity of the hemostatic mechanism results in intravascular thrombus formation.
- Etiological factors such as the presence of
- Atherosclerotic plaque, phlebitis and septicemia may cause thrombosis, leading to impaired blood flow to the effected tissues and possible serious pathological consequences.
- heparins are ill-defined mixtures of sulfated polysaccharides that bind to, and thus potentiate the action of antithrombin III.
- Antithrombin III is a naturally occurring inhibitor of the activated clotting factors IXa, Xa, XIa, thrombin and probably Xlla (see Jaques, Pharmacol . Rev. 1980, 31 , pp. 99-166).
- the vitamin K antagonists act indirectly by inhibiting the post-ribosomal carboxylations of the vitamin K dependent coagulation factors II, VII, IX and X (see Hirsch, Semin . Thromb . Hemostasis 1986, 12, 1- 11). While effective therapies for the treatment of thrombosis, heparins and vitamin K antagonists have the unfortunate side effects of bleeding and marked
- Thrombin is a serine protease having trypsin-like specificity for the cleavage of sequence-specific ArgXxx peptide bonds.
- the cleavage event begins with an attack of the active site serine on the scissile bond of the substrate, resulting in the formation of a tetrahedral intermediate. This is followed by collapse of the tetrahedral intermediate to form an acyl enzyme and release of the amino terminus of the cleaved sequence. Hydrolysis of the acyl enzyme then releases the carboxy terminus.
- thrombin inhibitors A number of naturally occurring thrombin inhibitors have been reported. These include josumamide A from Theonella sp . (see Fusetani, et.
- Arylsulfonylarginine amides such as (2R, 4R) - 4-methyl-1- [N 2 - ⁇ (3-methyl-1,2,3,4-tetrahydro-8- quinolinyl)sulfonyl ⁇ -L-arginyl]-2-piperidinecarboxylate have been shown to be effective inhibitors of thrombin (see Okamoto, et. al. Thromb Res . 1976, 8, 77-82,
- Inhibitor design has benefitted from the knowledge of the mechanism of action and of the peptide sequences which are thought to bind in the catalytic site of thrombin, e.g., -Gly-Val-Arg-Gly- of fibrinogen (see Blomback, et. al., J. Biol . Chem . , 1972, 247, 1496- 512) , Ile-Pro-Arg-Ser- of prothrombin (see Magnussen, et. al., in: Reich, et. al., "Proteases and Biological Control," pp. 123-149 (1975)) and -Val-Pro-Arg-Gly- of factor XIII (see Takagi and Doolittle, Biochemistry 1974, 13, 750-6 and Nakamura, et. al., Biochem .
- Kettner and Shenvi disclose peptide boronic acid inhibitors of trypsin-like proteases of formula (1)
- R 1 is a substituted alkyl selected from the group consisting of -(CH 2 ) Z -X, - CH (CH 3 ) - (CH 2 ) 2 -X, -CH 2 -CH (CH 3 )-CH 2 -X, -(CH 2 ) 2 -CH(CH 3 )-X and - (CH 2 ) 2 -CH (C H3 ) -X, wherein
- W is an N-protecting group
- Y is a sequence of n amino acids such that the n+1 amino acid peptide Y-Lys or Y-Arg has an affinity for the active site of a trypsin-like protease
- n is an integer of from 1 to 10 and in which at least one amino acid is an
- Q 1 and Q 2 are the same or different and are selected from -OH, -COR 1 , -CONR 1 R 2 , -NR 1 R 2 or -OR 3 of Q 1 and Q 2 taken together form a diol residue;
- R 1 , R 2 and R 3 which may be the same or different, are C 1-10 alkyl, C 6-10 aryl, C 6- l oaralkyl, or phenyl substituted by up to three groups selected from C 1-4 alkyl, halogen and C 1-4 alkoxy;
- R 4 is hydrogen or C 1-10 alkyl;
- R 5 is a group -A-X; wherein A is -(CH 2 ) z - in which z is 2, 3, 4 or 5; -CH (CH 3 ) - (CH 2 ) 2 -; -CH 2 -CH(CH 3 )-CH 2 -; - (CH 2 ) 2 -CH (CH 3 ) -;
- tripeptide thrombin inhibitors comprised of 1- aminoboronic and 1-aminophosphonic acid analogs of 3- methoxy-propylglycine (see Claeson, et. al., US 07- 245428) and pentylglycine (see Cheng, et. al.,
- boropeptides have been disclosed with utility as a treatment for tumors, viral infections and arthritis (US 4963655A and EP
- Kleemann, et. al. disclose renin-inhibiting 1-amino boronic acid derivatives of formula (3) A 1 -A 2 -HN-CHR 2 -BXR 3 (YR 4 ) (3) in which A 1 denotes a radical of formulae (4-8).
- ⁇ l and Y 2 are independently
- a heteroatom which can be N, S, or O
- a divalent cyclic boro amide where said chain or ring contains from 2 to 20 carbon atoms
- ring contains from 2 to 20 carbon atoms
- aryl is phenyl, naphthyl or biphenyl substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), -CN, C1-C10-alkyl, C3-C8- cycloalkyl, C2-C10-alkenyl, C2-C10-alkynyl, methylenedioxy, -R 8 , -OR 8 , -NO 2 , -CF 3 , -S(O) r R 7 , -NR 8 R 9 , -COR 8 , -CO 2 R 8 ' -CONR 8 R 9 , NR 8 COR 9 ;
- heteroaryl wherein heteroaryl is an
- substituents are members selected from the group consisting of halo (F, Cl, Br, I) , -CN, C1-C10-alkyl, C3-C8-cycloalkyl, C2-C10-alkenyl, C2-C10-alkynyl, -R 8 , -OR 8 , -NO 2 , -CF 3 , -S(O) r R 7 , -NR 8 R 9 , -COR 8 , -CO 2 R 8 ' -CONR 8 R 9 , NR 8 COR 9 , NRCO 2 R 9 ,
- R 3 is H, phenyl or C1-C4-alkyl
- R 4 is H or phenylsulfonyl
- R 5 and R 6 are hydrogen or when taken together from a six membered aromatic ring optionally substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), -CN, C1-C10-alkyl,
- R 8 and R 9 are independently
- R 10 and R 11 are independently
- R 12 is
- n 0 to 6;
- n 3 or 4;
- p 0 to 2;
- r is 0 to 2;
- t 1 to 5
- E is -CO-, -SO 2 -, -CH 2 - or a single bond
- F is -CO-; and pharmaceutically acceptable salts thereof.
- Preferred compounds of formula (I) are those compounds wherein R 1 is phenyl and biphenyl containing
- Trp tryptophan
- pinanediol boronic acid ester and the pinacol boronic acid ester are abbreviated "-C 10 H 16 " and "-C 6 H 12 " respectively.
- diols useful for deriving boronic acid esters are 1,2- ethanediol, 1,3-propanediol, 1,2-propanediol, 2,3- butanediol, 1,2-diisopropylethanediol, 5,6-decanediol, 1,2-dicyclohexylethanediol.
- the compounds of the present invention contain one or more chiral centers and that these stereoisomers may possess distinct physical and biological properties.
- the present invention comprises all of the stereoisomers or mixtures thereof. If the pure enantiomers or diastereomers are desired, they may be prepared using starting materials with the appropriate stereochemistry, or may be separated from mixtures of undesired stereoisomers by standard
- the compounds of formula (I) can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being affected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the chemical transformations proposed and this will sometimes require judgment as to the order of synthetic steps or selection of particular process scheme used from that shown below in order to obtain a desired compound of the invention.
- Scheme 1 Synthesis of Thrombin Inhibitors
- Reagents a. IBCF, NMM, RCO 2 H, Et 3 N, 0 °C, b. NaN 3 , c. H 2 , Pd(OH) 2 /C, HCl,d. DMAP, aminoiminomethanesulfonic acid, e. phenylboronic acid
- Amine hydrochloride 1 is readily available via the procedure of Kettner and Shenvi (EP 0293881 A2). There are numerous synthetic methods by which to prepare amide 2, however, competing with amide formation is the cyclization of 1 to afford a complex mixture containing the desired amide and the corresponding N- acylboroproline. Since purification at this stage is unfeasible, choosing the correct method for amide formation is crucial to obtaining 2 in a purity suitable for subsequent synthetic transformations.
- isobutyl mixed anhydride is generated by dissolving the carboxylic acid component in tetrahydrofuran and adding one equivalent of N-methylmorpholine. The solution is cooled to 0 °C and one equivalent of isobutyl
- the preferred method for the preparation of azide 3 is by reaction of 2 with sodium azide (1.1 eq) in dimethylformamide at 70 °C for 2 hours.
- the azide displacement may also be performed prior to amide formation. This is the preferred method in cases where the rate of amide formation is slow relative to the rate of cyclization.
- Azide 4 is prepared by a modification of the procedure of Kettner and Shenvi (EP 0293881 A2) as shown in Scheme 2.
- bromide 5 is reacted with sodium azide, followed by homologation to give 6, chloride displacement to afford 7 and acidic hydrolysis to give 4. Amide formation between 4 and the carboxylic acid component then affords 3 directly.
- Reagents a . NaN 3 b . CHCl 2 Li, ZnCl 2 , c . LiN(TMS) 2 , d. 4M HCl, dioxane
- Reduction of azide 3 to amine 8 may be accomplished by hydrogenation over precious metal catalysts.
- the preferred catalyst for this transformation is Pearlman's catalyst (palladium hydroxide on carbon).
- the amine is typically isolated as the hydrochloride salt. Isolation of 8 as the free base typically results in lowered yields. Salts of 8 which may confer superior physical properties may be preferred over the hydrochloride salt.
- Formamidination of amine 8 may be accomplished using cyanamide. Due to the low reactivity of amine 8, however, the preferred method for this transformation is reaction with 4-dimethylaminopyridine (DMAP) and
- Cleavage of pinanediol ester 9 may be accomplished using anhydrous boron trichloride according to the procedure of Matteson and Ray (J. Am . Chem . Soc . 1980, 102, 7588). This method, however, is strongly Lewis acidic and leads to partial destruction of the
- the preferred method for water soluble boronic acids is a transesterification reaction that is run in the presence of excess phenylboronic acid.
- the free boronic acid 10 may then be isolated using cation exchange chromatography.
- the isothiouronium functionalized analogs 11/12 are prepared from bromide 2 according to the procedure of Kettner and Shenvi (EP 0293881 A2).
- Inhibitors containing a sulfonamide in place of a carboxamide are prepared from either 1 or 4 by reaction with a sulfonyl chloride in the presence of a hindered amine (Scheme 3). The product sulfonamide 13 is then converted to the guanidinium 14 or isothiouronium 15 in the same manner as the corresponding carboxamides.
- Inhibitors containing the borolysine moiety are prepared analogously to those containing boroarginine according to Kettner and Shenvi (EP 0293881 A2).
- Novel biaryls synthesized in this invention are prepared through palladium catalyzed coupling of an appropriate arylmetal species to the aryl halide of choice using the methods described in Negishi, et. al., Org. Synth . 1987, 66, 61-14 , and references cited within.
- Part B ( +) -Pinanediol 4-azido-1 (R) -(4-phenylbenzoyl) aminobutane-1-boronate.
- (+)- pinanediol 4-azido-1 (R)-(4-phenylbenzoyl)aminobutane-1- boronate (3.04 g, 6.44 mmol) in methanol (30 mL) was added Pearlman' s catalyst Pd(OH) 2 /C, 200 mg) and 1 M hydrochloric acid (6.5 mL, 6.5 mmol).
- the mixture was placed on a Parr apparatus and hydrogenated at 50 psi for 3 hours.
- the mixture was filtered using CeliteTM, washed with methanol and the filtrate concentrated in vacuo .
- the resulting amorphous solid was dissolved in water and washed with ether.
- the compounds of formula (I) are useful as inhibitors of trypsin-like enzymes, notably human thrombin,
- these compounds are indicated for use in the prevention or treatment of physiological reactions catalyzed by the aforesaid enzymes such as blood coagulation and inflammation.
- substrate H-D-Phe-Pip-Arg-pNA (S-2238, Kabi) is cleaved by thrombin, liberating the p-nitroanalide group which absorbs light at 405 nm. Enzyme activity is measured in both the presence and absence of inhibitor. A decrease in absorbance at 405 nm in the presence of inhibitor is indicative of thrombin inhibition.
- the compounds of formula (I) have anti- thrombogenic properties, they may be employed when an anti-thrombogenic agent is indicated, such as for control of the coagulation or the fibrinolysis system in mammals or they may be added to blood for the purpose of preventing coagulation or the blood due to contact with blood collecting or distribution containers, tubing or apparatus.
- these compounds may be administered orally or parenterally to a host to obtain an anti- thrombogenic effect.
- the dosage of the active compound depends on the mammalian species, body weight, age, and mode of administration as will be obvious to one skilled in the art. In the case of large mammals such as humans, the compounds may be administered alone or in combination with
- pharmaceutical carriers or diluents at a dose of from 0.02 to 15 mg/Kg to obtain the anti-thrombogenic effect, and may be given as a single dose or in divided doses or as a sustained release formulation.
- Pharmaceutical carriers or diluents are well known and include sugars, starches and water, which may be used to make tablets, capsules, injectable solutions or the like which can serve as suitable dosage forms for administration of the compounds of this
- Osol is a standard reference text which discloses suitable pharmaceutical carriers and dosage forms .
- the disclosure of this text is hereby incorporated by reference for a more complete teaching of suitable dosage forms for administration of the compounds of this invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Novel boronic acid derivatives of formula (I), which are useful inhibitors of trypsin-like enzymes, are disclosed: R?1-Z-CHR2-BY1Y2¿.
Description
Title
Boronic Acid and Ester Inhibitors of Thrombin
Field of the Invention
This invention relates to the discovery of new boronic acid derivatives which are inhibitors of
thrombin and pharmaceutical compositions thereof.
Background of the Invention
Hemostasis is the normal physiological process in which bleeding from an injured blood vessel is arrested. It is a dynamic and complex process in which thrombin plays a key role. Blood coagulation may occur through either of two cascades of zymogen activations, the extrinsic and intrinsic pathways of the coagulation cascade. The last protease in each pathway is thrombin, which acts to hydrolyze four small peptides (two FpA and two FpB) from each molecule of fibrinogen, thus
deprotecting its polymerization sites. Once formed, the linear fibrin polymers may be cross-linked by factor Xllla, which is itself activated by thrombin. In addition, thrombin is a potent activator of platelets, upon which it acts at specific receptors. Thrombin activation of platelets leads to aggregation of the cells and secretion of additional factors that further accelerate the creation of a hemostatic plug. Thrombin also potentiates its own production by the activation of factors V and VIII (see Hemker and Beguin in: Jolles, et. al., "Biology and Pathology of Platelet Vessel Wall Interactions," pp. 219-26 (1986), Crawford and Scrutton in: Bloom and Thomas, "Haemostasis and Thrombosis," pp. .47-77, (1987), Bevers, et. al., Eur. J. Biochem . 1982, 122, 429-36, Mann, Trends Biochem . Sci . 1987, 12, 229- 33).
Thrombosis may be regarded as the pathological condition wherein improper activity of the hemostatic
mechanism results in intravascular thrombus formation. Etiological factors such as the presence of
atherosclerotic plaque, phlebitis and septicemia may cause thrombosis, leading to impaired blood flow to the effected tissues and possible serious pathological consequences.
Currently, two of the most effective classes of drugs in clinical use as anticoagulants are the heparins and the vitamin K antagonists. The heparins are ill-defined mixtures of sulfated polysaccharides that bind to, and thus potentiate the action of antithrombin III.
Antithrombin III is a naturally occurring inhibitor of the activated clotting factors IXa, Xa, XIa, thrombin and probably Xlla (see Jaques, Pharmacol . Rev. 1980, 31 , pp. 99-166). The vitamin K antagonists, of which warfarin is the most well-known example, act indirectly by inhibiting the post-ribosomal carboxylations of the vitamin K dependent coagulation factors II, VII, IX and X (see Hirsch, Semin . Thromb . Hemostasis 1986, 12, 1- 11). While effective therapies for the treatment of thrombosis, heparins and vitamin K antagonists have the unfortunate side effects of bleeding and marked
interpatient variability, resulting in a small and unpredictable therapeutic safety margin. The use of direct acting thrombin inhibitors is expected to
alleviate these problems.
Thrombin is a serine protease having trypsin-like specificity for the cleavage of sequence-specific ArgXxx peptide bonds. As with other serine proteases, the cleavage event begins with an attack of the active site serine on the scissile bond of the substrate, resulting in the formation of a tetrahedral intermediate. This is followed by collapse of the tetrahedral intermediate to form an acyl enzyme and release of the amino terminus of the cleaved sequence. Hydrolysis of the acyl enzyme then releases the carboxy terminus.
A number of naturally occurring thrombin inhibitors have been reported. These include nazumamide A from Theonella sp . (see Fusetani, et. al., Tetrahedron Lett . 1991, 32, 7073-4), cyclotheonamide A from Theonella sp . (see Fusetani, et. al., J. Am. Chem . Soc . 1990, 112, 7053-4), amblyommin from Amblyomma hebraeum (see Bonin, et. al., EP 345614), hirudin from Hirudo medicinalis, recombinant versions of hirudin and hirudin fragments (see Rigbl and Jackson, EP 352903, Koerwer, WO 9109946, Meyer, et. al., WO 9108233, Dawson, et. al., WO 9109125, Maraganore, et. al., WO 9102750 and Maraganore, EP
333356).
Synthetic thrombin inhibitors have also been
disclosed. Arylsulfonylarginine amides such as (2R, 4R) - 4-methyl-1- [N2- {(3-methyl-1,2,3,4-tetrahydro-8- quinolinyl)sulfonyl}-L-arginyl]-2-piperidinecarboxylate have been shown to be effective inhibitors of thrombin (see Okamoto, et. al. Thromb Res . 1976, 8, 77-82,
Ohshiro, et. al., Blood Vessel 1983, 14, 216-8), as have compounds containing constrained arginine mimics such as (2-naphthylsulfonylglycyl)-4-amidino- phenylalanyl piperidide (see Stuerzebecher, et. al., Thromb . Res . 1983, 29, 635-42), 1-[2-[5- (dimethylamino)naphth-1-ylsulfonamido]-3-(2- iminohexahydropyrimidin-5-yl)propanoyl]-4- methylpiperidine dihydrochloride (see Ishikawa, JP
88227572 and Ishikawa and Inamura, JP 88227573) , N- (trans-4-amino-methylcyclohexylcarbonyl)-4-0-(2- picolyl)-L-tyrosine 4-acetanilide dihydrochloride (see Okamoto, et. al., EP 217286) and 4- [(aminoiminomethyl)amino] benzoic acid esters (see Fuji, et. al., DE 3005580, Matsuoka, et. al., Jpn . J.
Pharmacol . 1989, 51 , 455-63, and Takeshita, et. al., EP 435235).
Inhibitor design has benefitted from the knowledge of the mechanism of action and of the peptide sequences
which are thought to bind in the catalytic site of thrombin, e.g., -Gly-Val-Arg-Gly- of fibrinogen (see Blomback, et. al., J. Biol . Chem . , 1972, 247, 1496- 512) , Ile-Pro-Arg-Ser- of prothrombin (see Magnussen, et. al., in: Reich, et. al., "Proteases and Biological Control," pp. 123-149 (1975)) and -Val-Pro-Arg-Gly- of factor XIII (see Takagi and Doolittle, Biochemistry 1974, 13, 750-6 and Nakamura, et. al., Biochem .
Biophys . Res . Commun . 1974, 58, 250-256). This class of mechanism-based inhibitors are exemplified by the tripeptide aldehyde D-Phe-Pro-N-Me-Arg-H (see Bajusz, et. al., J. Med . Chem. 1990, 33, 1729-35), the
chloromethyl ketone Ac-(D)-Phe-Pro-ArgCH2Cl (see Kettner and Shaw, Thromb . Res . 1979, 14, 969-73) and the trifluoromethyl ketone D-Phe-Pro-ArgCF3 (see Kolb, et. al., US 697987).
Kettner and Shenvi (EP 293881, published June 12, 1988) , disclose peptide boronic acid inhibitors of trypsin-like proteases of formula (1)
R1-[(A3)q(A2)p(A1)o]n-ΝH-CHR2-BY1Y2 (1) wherein Y1 and Y2, independently, are hydroxyl or fluoro or, taken together, form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising 1 to about 20 carbon atoms and, optionally, a heteroatom which can be N, S, or 0; R2 is a substituted alkyl selected from the group consisting of -(CH2)Z-X, - CH (CH3) - (CH2) 2-X, -CH2-CH (CH3)-CH2-X, -(CH2)2-CH(CH3)-X and - (CH2) 2-CH (CH3) -X, where X is -NH2, -NH-C (NH)-NH2 or -S-C (NH)-NH2, and z is 3 to 5; n, o, p and q are, independently, either 0 or 1; A1, A2 and A3 are, independently, amino acids of L- or D-configuration selected from the group consisting of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, lle, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr and Val; and R1
is a peptide comprised of 1 to about 20 amino acids, an acyl or a sulfonyl group comprised of 1 to about 20 carbon atoms, H, or an N-terminal protecting group. In this disclosure, Kettner and Shenvi demonstrated that the pinanediol esters of boropeptides are
pharmacologically equivalent to the corresponding boronic acids.
Metternich (EP 0471651 A2) discloses borolysine thrombin inhibitors of formula (2)
W-Y-NR4-CHR5-BQ1Q2 (2) wherein W is an N-protecting group; Y is a sequence of n amino acids such that the n+1 amino acid peptide Y-Lys or Y-Arg has an affinity for the active site of a trypsin-like protease; where n is an integer of from 1 to 10 and in which at least one amino acid is an
unnatural amino acid having a hydrophobic side chain; Q1 and Q2 are the same or different and are selected from -OH, -COR1, -CONR1R2, -NR1R2 or -OR3 of Q1 and Q2 taken together form a diol residue; R1, R2 and R3 which may be the same or different, are C1-10alkyl, C6-10aryl, C6- loaralkyl, or phenyl substituted by up to three groups selected from C1-4alkyl, halogen and C1-4alkoxy; R4 is hydrogen or C1-10alkyl; R5 is a group -A-X; wherein A is -(CH2)z- in which z is 2, 3, 4 or 5; -CH (CH3) - (CH2)2-; -CH2-CH(CH3)-CH2-; - (CH2) 2-CH (CH3) -; - (CH2) 2-C (CH3) 2-; CH(CH3)-(CH2)3-; -CH2-CH (CH3) - (CH2) 2-; -CH2-CH2-CH (CH3)- CH2-; -(CH2)3-CH(CH3)-; - (CH2) 3-C (CH3)2 : C6-10aryl C6- 10aralkyl and X is -NH2, -NH-C (NH) -NH2, -S-C (NH) -NH2, -N3, -C1-4alkoxy, C1-4alkylthio or Si(CH3)3 or R4 and R5 taken together form a trimethylene group and the asymmetric carbon atom may have the D- or L-configuration or represent any mixture of these.
Surprising for their lack of a basic residue at P1 are tripeptide thrombin inhibitors comprised of 1-
aminoboronic and 1-aminophosphonic acid analogs of 3- methoxy-propylglycine (see Claeson, et. al., US 07- 245428) and pentylglycine (see Cheng, et. al.,
"Symposium on Thrombosis and Hemostasis," 1991,
Amsterdam, Abstract 2150).
In addition to thrombin inhibition, boropeptides have been disclosed with utility as a treatment for tumors, viral infections and arthritis (US 4963655A and EP
354522A) , emphysema (US 4499082A) , hypertension (EP 315574A) and as factor VII/Vila inhibitors (WO
8909612A). Kleemann, et. al. (AU A-24693/88) disclose renin-inhibiting 1-amino boronic acid derivatives of formula (3) A1-A2-HN-CHR2-BXR3(YR4) (3) in which A1 denotes a radical of formulae (4-8).
R1NR6-CHR5-CO- (4) R1CHR12-CHR5-CO- (5)
R1NR6-CHR5-CHR7-CHR8-CHR9-CO- (6)
R1CHR12-CHR5-CHR7-CHR8-CHR9-CO- (7)
R10-(CH2)n-CH(CH2)mR11-CO- (8) Despite the foregoing, more efficacious and specific thrombin inhibitors are needed as potentially valuable therapeutic agents for the treatment of thrombosis.
None of the cited references describe or suggest the new thrombin-inhibiting boronic acid derivatives of the present invention.
Summary of Invention
The present invention pertains to novel compounds of formula (I):
R1-Z-CHR2-BY1Y2
(I)
wherein
γl and Y2 are independently
a) -OH,
b) -F,
c) -NR3R4, or
d) C1-C8-alkoxy;
Y1 and Y2 when taken together can form
a) a cyclic boron ester where said chain or ring
contains from 2 to 20 carbon atoms and,
optionally, a heteroatom which can be N, S, or O, b) a divalent cyclic boro amide where said chain or ring contains from 2 to 20 carbon atoms,
c) a cyclic boro amide-ester where said chain or
ring contains from 2 to 20 carbon atoms;
Z is
a) -(CH2)mCONR8-,
b) -(CH2)mCSNR8-,
c) -(CH2)mSO2NR8-,
d) -(CH2)mCO2-,
e) -(CH2)mC(S)O-, or
f) -(CH2)mSO2O-;
R1 is
a) -(CH2)p-aryl, wherein aryl is phenyl, naphthyl or biphenyl substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), -CN, C1-C10-alkyl, C3-C8- cycloalkyl, C2-C10-alkenyl, C2-C10-alkynyl, methylenedioxy, -R8, -OR8, -NO2, -CF3, -S(O)rR7,
-NR8R9 , -COR8 , -CO2R8 ' -CONR8R9 , NR8COR9 ;
b) heteroaryl, wherein heteroaryl is an
unsubstituted, monosubstituted or disubstituted; i) 5- or 6-membered aromatic ring, which
contains from 1 to 3 heteroatoms selected from the group consisting of O, N, and S, ii) quinolinyl,
iii) isoquinolinyl,
iv) benzopyranyl,
v) benzothiophenyl,
vi) benzofuranyl,
vii) 5,6,7,8-tetrahydroquinolinyl
viii) 5,6,7,8-tetrahydroisoquinolinyl and wherein the substituents are members selected from the group consisting of halo (F, Cl, Br, I) , -CN, C1-C10-alkyl, C3-C8-cycloalkyl, C2-C10-alkenyl, C2-C10-alkynyl, -R8, -OR8, -NO2, -CF3, -S(O)rR7, -NR8R9, -COR8, -CO2R8' -CONR8R9, NR8COR9, NRCO2R9,
R2 is
a) -(CH2)n-NHC (NH)NH2, b) -(CH2)n-NHC (NH)NHCOCH3,
c) -(CH2)n-SC(NH)NH2,
d) -(CH2)n-SC(NH)NHCOCH3,
e) -(CH2)n-NH2, or
f) -(CH2)n-NH(2-pyridyl);
R3 is H, phenyl or C1-C4-alkyl;
R4 is H or phenylsulfonyl;
R5 and R6 are hydrogen or when taken together from a six membered aromatic ring optionally substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), -CN, C1-C10-alkyl,
C3-C8-cycloalkyl, C2-C10-alkenyl, C2-C10-alkynyl, -OR8, -NO2, -CF3, -S(O)rR7, -NR8R9, -COR8, -CO2R8' -CONR8R9' phenyl, benzyl, phenylethyl'
R7 is
a) phenyl,
b) C1-C4-alkyl,
c) C1-C4-alkoxy, or
d) -CF3;
R8 and R9 are independently
a) H,
b)
c) C3-C7-cycloalkyl,
d) C1-C8-alkyl;
R10 and R11 are independently
a) halo (F, Cl, Br, I),
b) -CN,
c) C1-C10-alkyl,
d) C3-C8-cycloalkyl,
e) C2-C10-alkenyl,
f) C2-C10-alkynyl,
g) -OR8,
h) -NO2,
i) -CF3,
j) -S(O)rR7,
k) -NR8R9,
l) -COR9,
m) -CO2R8
n) -CONR8R9''
R12 is
a) H,
b) C1-C4-alkyl,
c) phenyl,
d) benzyl
e) -COR7
f) -SO2R7
m is 0 to 6;
n is 3 or 4;
p is 0 to 2;
r is 0 to 2;
t is 1 to 5
E is -CO-, -SO2-, -CH2- or a single bond,
F is -CO-; and pharmaceutically acceptable salts thereof.
Preferred compounds of formula (I) are those compounds wherein R1 is phenyl and biphenyl containing
1-3 substituents selected from the series halo (F, Cl,
Br, I), C1-C10-alkyl, C3-C8-cycloalkyl, C2-C10-alkenyl,
C2-C10-alkynyl, -R8, -OR8, -NO2, -CF3, -S(O)rR7, -NR8R9,
-COR8, -CO2R8' -CONR8R9; NR8COR9;
R2 is
a) -(CH2)3-NHC(NH)NH2, or
b) -(CH2)3-SC(NH)NH2.
More preferred are those preferred compounds wherein Z is -(CH2)mCONR8-.
Most preferred are those more preferred compounds listed below:
N1-(4-phenylbenzoyl)-(R)-boroarginine, hydrochloride N1-(3-phenoxybenzoyl)-(R)-boroarginine, hydrochloride N1-(1-fluorenonyl)-(R)-boroarginine, hydrochloride
N1-(4-[1-butyl]benzoyl)-(R)-boroarginine, hydrochloride N1-(2-benzoylbenzoyl)-(R)-boroarginine, hydrochloride N1-(5-phenyl-2-furoyl)-(R)-boroarginine, hydrochloride N1-(3-[N-benzyloxycarbonyl-N-methylamino]-4-[1-butyl]- benzoyl)-(R)-boroarginine, hydrochloride
N1-(2-phenyl-4-isoquinolyl)-(R)-boroarginine,
hydrochloride
N1-(4-cyclohexylbenzoyl)-(R)-boroarginine,
hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-(R)-boroarginine,
hydrochloride
Illustrative of the compounds of this invention are the following:
N1-(4-phenylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(3-phenylbenzoyl)-(R)-b)roarginine (+)-pinanediol, bisulfite
N1-(3-phenoxybenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-[4-pyridyl]benzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-benzoylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(3-benzoylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-benzoylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(3-[N-benzyloxycarbonyl ] aminobenzoyl )-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(3-[N-benzyloxycarbonyl-N-methyl ]aminobenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(4-ethylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-n-propylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-isopropylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-n-butylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-tert-butylbenzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(4-n-hexylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(4-cyclohexylbenzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-[N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(4-n-butyloxybenzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(4-[N-cyclopropylcarbonyl ]aminobenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(4-[N-cyclohexylcarbonyl]aminobenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(4-[N-(4-methoxy)benzoyl]aminobenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1- (2-[2-phenyl]benzyloxycarbonylbenzoyl)-(R) - boroarginine (+)-pinanediol, bisulfite
N1- (2-[1-naphthyl]benzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(4-phenylbenzoyl)-(R)-borothioarginine (+) - pinanediol, hydrobromide
N1-(3-phenylbenzoyl)-(R)-borothioarginine (+) - pinanediol, hydrobromide
N1-(3-phenoxybenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(2-benzoylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(3-benzoylbenzoyl)-(R)-borothioarginine ( +) - pinanediol, hydrobromide
N1-(4-benzoylbenzoyl)-(R)-borothioarginine ( +) - pinanediol, hydrobromide
N1-(3-[N-benzyloxycarbonyl ]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(3-[N-benzyloxycarbonyl-N-methyl ]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(4-ethylbenzoyl)-(R)-borothioarginine (+)-pinanediol, hydrobromide
N1-(4-n-propylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-isopropylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-n-butylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-tert-butylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-n-hexylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-cyclohexylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(2-[N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(4-n-butyloxybenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-[N-cyclopropylcarbonyl ]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(4-[N-cyclohexylcarbonyl ]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(4-[N-(4-methoxy)benzoyl]aminobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-(2-[2-phenylbenzyloxycarbonyl]benzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-[1-naphthyl]benzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-([2-anthraquinonyl]carbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)-boroarginine
(+)-pinanediol, bisulfite
N1-([2-anthraquinony1]carbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-([2-fluoren-9-onyl]carbonyl)-(R)-borothiohomoarginine
(+)-pinanediol, hydrobromide
N1-([2-fluoren-9-onyl]carbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-([2-fluoren-9-onyl]carbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-([3-fluoren-9-onyl]carbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-([3-fluoren-9-onyl]carbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-([4-fluoren-9-onyl]carbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-([4-fluoren-9-onyl]carbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(1-naphthoyl)-(R)-borothioarginine (+)-pinanediol, hydrobromide
N1-(1-naphthoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)- (R)-borothioarginine (+)-pinanediol, hydrobromide N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)-boroarginine (+) -pinanediol, bisulfite
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R)- boroarginine ( +)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)- (R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- boroarginine (+)-pinanediol, bisulfite
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- boroarginine (+)-pinanediol, bisulfite
N1-(2-[5-phenyl]furylcarbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-[5-phenyl]thiophenylcarbonyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(2-[5-phenyl]furylcarbonyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(2-[5-phenyl]thiophen-ylcarbonyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(3-[6-phenyl]pyridylcarbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(3-[5-benzyloxy]pyridylcarbonyl)-(R)-boroarginine
(+)-pinanediol, bisulfite
N1-(3-[6-phenyl]pyridylcarbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-(3-[5-benzyloxy]pyridylcarbonyl)-(R)-borothioarginine
(+)-pinanediol, hydrobromide
N1-(2-benzopyronylcarbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-benzopyronylcarbonyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(3-isoquinolinylcarbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)-boroarginine (+)-pinanediol, bisulfite
N1-(3-isoquinolinylcarbonyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)- borothioarginine (+)-pinanediol, hydrobromide
N1-(2-isoquinolinylcarbonyl)-(R)-boroarginine (+)- pinanediol, bisulfite
N1-(2-isoquinolinylcarbonyl)-(R)-borothioarginine (+)- pinanediol, hydrobromide
N1-(4-p-enylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(3-phenylbenzoy1)-(R)-boroarginine, hydrochloride
N1-(3-phenoxybenzoyl)-(R)-boroarginine, hydrochloride
N1-(4-[4-pyridyl]benzoyl)-(R)-boroarginine,
hydrochloride
N1-(2-benzoylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(3-benzoylbenzoyl)-(R)-boroarginine, hydrochloride N1-(4-benzoylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(3-[N-benzyloxycarbonyl]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(3-[N-benzyloxycarbonyl-N-methyl ]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(4-ethylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(4-n-propylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(4-isopropylbenzoyl)-(R)-boroarginine, hydrochloride N1-(4-tert-butylbenzoyl)-(R)-boroarginine,
hydrochloride
N1-(4-n-hexylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(4-cyclohexylbenzoyl)-(R)-boroarginine,
hydrochloride
N1-(2-[N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(4-n-butyloxybenzoyl)-(R)-boroarginine,
hydrochloride
N1-(4-[N-cyclopropylcarbonyl]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(4-[N-cyclohexylcarbonyl ]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(4-[N-(4-methoxy)benzoyl]aminobenzoyl)-(R)- boroarginine, hydrochloride
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(2-[2-phenyl]benzyloxycarbonylbenzoyl)-(R)- boroarginine, hydrochloride
N1- (2-[1-naphthyl]benzoyl)-(R)-boroarginine,
hydrochloride
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-boroarginine, hydrochloride
N1-([2-anthraquinonyl]carbonyl)-(R)-boroarginine, hydrochloride
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)-boroarginine, hydrochloride
N1-([2-fluoren-9-onyl]carbonyl)-(R)-boroarginine, hydrochloride
N1-([3-fluoren-9-onyl]carbonyl)-(R)-boroarginine, hydrochloride
N1-(1-naphthoyl)-(R)-boroarginine, hydrochloride
N1-([4-fluoren-9-onyl]carbonyl)-(R)-boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)-boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)-boroarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R) - boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)- (R)-boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- boroarginine, hydrochloride
N1-(2-[5-phenyl]furylcarbonyl)-(R)-boroarginine, hydrochloride
N1-(2-[5-phenyl]thiophenylcarbonyl)-(R)-boroarginine, hydrochloride
N1-(2-benzopyronylcarbonyl)-(R)-boroarginine,
hydrochloride
N1-(2-isoquinolinylcarbonyl)-(R)-boroarginine,
hydrochloride
N1-(3-isoquinolinylcarbonyl)-(R)-boroarginine,
hydrochloride
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)-boroarginine, hydrochloride
N1-(4-phenylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(3-phenylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(3-phenoxybenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(2-benzoylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(3-benzoylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-benzoylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(3-[N-benzyloxycarbonyl ]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(3-[N-benzyloxycarbonyl-N-methyl ]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(4-ethylbenzoyl)-(R)-borothioarginine, hydrochloride N1-(4-n-propylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-isopropylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-n-butylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-te.rt-butylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-n-hexylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-cyclohexylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(2-[N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(4-n-butyloxybenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(4-[N-cyclopropylcarbonyl]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(4-[N-cyclohexylcarbonyl]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(4-[N-(4-methoxy)benzoyl]aminobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-borothioarginine, hydrochloride
N1-(2-[2-phenylbenzyloxycarbonyl]benzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-[1-naphthyl]benzoyl)-(R)-borothioarginine, hydrochloride
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-borothioarginine, hydrochloride
N1-([2-anthraquinonyl]carbonyl)-(R)-borothioarginine, hydrochloride
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)- borothioarginine, hydrochloride
N1-([2-fluoren-9-onyl]carbonyl)-(R)- borothiohomoarginine, hydrochloride
N1-([2-fluoren-9-onyl]carbonyl)-(R)-borothioarginine, hydrochloride
N1-([3-fluoren-9-onyl]carbonyl)-(R)-borothioarginine, hydrochloride
N1-([4-fluoren-9-onyl]carbonyl)-(R)-borothioarginine, hydrochloride
N1-(1-naphthoyl)-(R)-borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)-
(R)-borothioarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- borothioarginine, hydrochloride
N1- (2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-borothioarginine,
hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- borothioarginine, hydrochloride
N1-(2-[5-phenyl]furylcarbonyl)-(R)-borothioarginine, hydrochloride
N1-(2-[5-phenyl]thiophenylcarbonyl)-(R)- borothioarginine, hydrochloride
N1-(3-[6-phenyl]pyridylcarbonyl)-(R)-boroarginine, hydrochloride
N1-(3-[5-benzyloxy]pyridylcarbonyl)-(R)-boroarginine, hydrochloride
N1-(3-[6-phenyl]pyridylcarbonyl)-(R)-borothioarginine, hydrochloride
N1-(3-[5-benzyloxy]pyridylcarbonyl)-(R)- borothioarginine, hydrochloride
N1-(2-benzopyronylcarbonyl)-(R)-borothioarginine, hydrochloride
N1-(3-isoquinolinylcarbonyl)-(R)-borothioarginine, hydrochloride
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)- borothioarginine, hydrochloride
N1-(2-isoquinolinylcarbonyl)-(R)-borothioarginine, hydrochloride
N1-(4-phenylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(3-phenylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(3-phenoxybenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-[4-pyridyl]benzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(2-benzoylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(3-benzoylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-benzoylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(3-[N-benzyloxycarbonyl]aminobenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(3-[N-benzyloxycarbonyl-N-methyl ]aminobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(4-ethylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-n-propylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-isopropylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-tert-butylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-n-hexylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-cyclohexylbenzoyl)-(R)-borolysine ( +) -pinanediol, hydrochloride
N1- (2- [N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(4-n-butyloxybenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-[N-cyclopropylcarbonyl]aminobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(4-[N-cyclohexylcarbonyl ]aminobenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(4-[N-(4-methoxy)benzoyl]aminobenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-[2-phenyl]benzyloxycarbonylbenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(2-[1-naphthyl]benzoyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-([2-anthraquinonyl]carbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-([2-fluoren-9-onyl]carbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-([3-fluoren-9-onyl]carbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(1-naphthoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-([4-fluoren-9-onyl]carbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)-
(R)-borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- borolysine (+)-pinanediol, hydrochloride
N1-(2-[5-phenyl]furylcarbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-[5-phenyl]thiophen-ylcarbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-benzopyronylcarbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-isoquinolinylcarbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(3-isoquinolinylcarbonyl)-(R)-borolysine (+)- pinanediol, hydrochloride
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)-borolysine
(+)-pinanediol, hydrochloride
N1-(4-phenylbenzoyl)-(R)-borolysine, hydrochloride
N1-(3-phenylbenzoyl)-(R)-borolysine, hydrochloride
N1-(3-phenoxybenzoyl)-(R)-borolysine, hydrochloride
N1-(4-[4-pyridyl]benzoyl)-(R)-borolysine, hydrochloride
N1-(2-benzoylbenzoyl)-(R)-borolysine, hydrochloride N1-(3-benzoylbenzoyl)-(R)-borolysine, hydrochloride
N1-(4-benzoylbenzoyl)-(R)-borolysine, hydrochloride
N1-(3-[N-benzyloxycarbonyl ]aminobenzoyl)-(R)-borolysine, hydrochloride
N1-(3-[N-benzyloxycarbonyl-W-methyl ]aminobenzoyl)-(R)- borolysine, hydrochloride
N1-(4-ethylbenzoyl)-(R)-borolysine, hydrochloride
N1-(4-n-propylbenzoyl)-(R)-borolysine, hydrochloride
N1-(4-isopropylbenzoyl)-(R)-borolysine, hydrochloride
N1-(4-tert-butylbenzoyl)-(R)-borolysine, hydrochloride N1-(4-n-hexylbenzoyl)-(R)-borolysine, hydrochloride
N1-(4-cyclohexylbenzoyl)-(R)-borolysine, hydrochloride
N1-(2-[N-(2-phenylethyl)carbonyl]aminobenzoyl)-(R)- borolysine, hydrochloride
N1-(4-n-butyloxybenzoyl)-(R)-borolysine, hydrochloride
N1-(4-[N-cyclopropylcarbonyl ] aminobenzoyl)-(R)- borolysine, hydrochloride
N1-(4-[N-cyclohexylcarbonyl ] aminobenzoyl)-(R)- borolysine, hydrochloride
N1-(4-[N-(4-methoxy)benzoyl] aminobenzoyl)-(R)- borolysine, hydrochloride
N1-(4-[4-methoxy]phenylbenzoyl)-(R)-borolysine, hydrochloride
N1-(2-[2-phenyl]benzyloxycarbonylbenzoyl)-(R) - borolysine, hydrochloride
N1-(2-[1-naphthyl]benzoyl)-(R)-borolysine,
hydrochloride
N1-(4-[4-carboxy]phenylbenzoyl)-(R)-borolysine, hydrochloride
N1-([2-anthraquinonyl]carbonyl)-(R)-borolysine, hydrochloride
N1-([2-dioxothioxanthinonyl]carbonyl)-(R)-borolysine, hydrochloride
N1-([2-fluoren-9-onyl]carbonyl)-(R)-borolysine, hydrochloride
N1-([3-fluoren-9-onyl]carbonyl)-(R)-borolysine, hydrochloride
N2-(1-naphthoyl)-(R)-borolysine, hydrochloride
N1-([4-fluoren-9-onyl]carbonyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-methoxybenzoyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-carboxamidobenzoyl)-(R)- borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-fluorobenzoyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-trifluoromethylbenzoyl)-(R)- borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-chlorobenzoyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-phenyl-5-hydroxybenzoyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-methoxybenzoyl)-(R) - borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-carboxamidobenzoyl)-
(R)-borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-fluorobenzoyl)-(R)- borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5- trifluoromethylbenzoyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-chlorobenzoyl)-(R)- borolysine, hydrochloride
N1-(2-methyl-4-[4-carboxy]phenyl-5-hydroxybenzoyl)-(R)- borolysine, hydrochloride
N1-(2-[5-phenyl]furylcarbonyl)-(R)-borolysine,
hydrochloride
N1-(2-[5-phenyl]thiophen-ylcarbonyl)-(R)-borolysine, hydrochloride
N1-(2-benzopyronylcarbonyl)-(R)-borolysine,
hydrochloride
N1-(2-isoquinolinylcarbonyl)-(R)-borolysine,
hydrochloride
N1-(3-isoquinolinylcarbonyl)-(R)-borolysine,
hydrochloride
N1-(2-phenyl-4-isoquinolinylcarbonyl)-(R)-borolysine, hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-R-borolysine,
hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-R-borolysine, (+)- pinanediol, hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-R-borothioarginine (+)- hydrobromide
N1-(2-methyl-4-phenylbenzoyl)-R-borothioarginine (+)- pinanediol, hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-R-boroarginine (+)- hydrochloride
N1-(2-methyl-4-phenylbenzoyl)-R-boroarginine (+)- pinanediol, bisulfite
Detailed Description of the Invention
Throughout the specification, the following conventional three-letter abbreviations for amino acid residues or amino acids apply:
Ala = alanine
Arg = arginine
Asn = asparagine
Asp = aspartic acid
Cys = cysteine
Gln = glutamine
Glu = glutamic acid
Gly = glycine
His = histidine
lle = isoleucine
Leu = leucine
Lys = lysine
Met = methionine
Phe = phenylalanine
Pro = proline
Ser = serine
Thr = threonine
Trp = tryptophan
Tyr = tyrosine
Val = valine
The prefix "boro" indicates amino acid residues where the carboxy group is replaced by a boronic acid (Formula I, Y1 and Y2 = -OH).
The pinanediol boronic acid ester and the pinacol boronic acid ester are abbreviated "-C10H16" and
"-C6H12" respectively. Other illustrations of diols useful for deriving boronic acid esters are 1,2- ethanediol, 1,3-propanediol, 1,2-propanediol, 2,3- butanediol, 1,2-diisopropylethanediol, 5,6-decanediol, 1,2-dicyclohexylethanediol.
Note that throughout the text when an alkyl substituent is mentioned, the normal alkyl structure is meant (e.g. butyl is n-butyl) unless otherwise
specified. However, in the definition of radicals above (e.g. R3) , both branched and straight chains are included in the scope of alkyl.
It is understood that many of the compounds of the present invention contain one or more chiral centers and that these stereoisomers may possess distinct physical and biological properties. The present invention comprises all of the stereoisomers or mixtures thereof. If the pure enantiomers or diastereomers are desired, they may be prepared using starting materials with the appropriate stereochemistry, or may be separated from mixtures of undesired stereoisomers by standard
techniques, including chiral chromatography and
recrystallization of diastereomeric salts.
Synthesis
The compounds of formula (I) can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being affected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the chemical transformations proposed and this will sometimes require judgment as to the order of synthetic steps or selection of particular process scheme used from that shown below in order to obtain a desired compound of the invention.
Scheme 1. Synthesis of Thrombin Inhibitors
Reagents: a. IBCF, NMM, RCO2H, Et3N, 0 °C, b. NaN3, c. H2, Pd(OH)2/C, HCl,d. DMAP, aminoiminomethanesulfonic acid, e. phenylboronic acid
Amine hydrochloride 1 is readily available via the procedure of Kettner and Shenvi (EP 0293881 A2).
There are numerous synthetic methods by which to prepare amide 2, however, competing with amide formation is the cyclization of 1 to afford a complex mixture containing the desired amide and the corresponding N- acylboroproline. Since purification at this stage is unfeasible, choosing the correct method for amide formation is crucial to obtaining 2 in a purity suitable for subsequent synthetic transformations.
Three methods are preferred for the preparation of 2. In the first, a solution of 1 in tetrahydrofuran or dichloromethane at 0 °C is treated sequentially with the desired acid chloride followed by two equivalents of triethylamine. The mixture is then allowed to warm to room temperature overnight. The second method is the mixed anhydride procedure of Anderson, et. al. ( J. Am . Chem . Soc . 1967, 89, 5012). In this method the
isobutyl mixed anhydride is generated by dissolving the carboxylic acid component in tetrahydrofuran and adding one equivalent of N-methylmorpholine. The solution is cooled to 0 °C and one equivalent of isobutyl
chloroformate is added. After 5 minutes, a solution of 1 in chloroform is added, followed by the addition of one equivalent of triethylamine. The mixture is
typically stirred at 0 °C for one hour followed by one to several hours at room temperature. The third method for amide formation is the hydroxybenzotriazole/DCC method of König and Geiger ( Chem . Ber. 1970, 103, 788- 98). Thus, to a solution of 1 and the carboxylic acid component in dimethylformamide or tetrahydrofuran at 0 °C is added N-methylmorpholine , 1-hydroxybenzotriazole hydrate (2 eq) and DCC (1.05 eq). The solution is allowed to warm to room temperature overnight.
The preferred method for the preparation of azide 3 is by reaction of 2 with sodium azide (1.1 eq) in dimethylformamide at 70 °C for 2 hours.
The azide displacement may also be performed prior to amide formation. This is the preferred method in cases where the rate of amide formation is slow relative to the rate of cyclization. Azide 4 is prepared by a modification of the procedure of Kettner and Shenvi (EP 0293881 A2) as shown in Scheme 2. Thus, bromide 5 is reacted with sodium azide, followed by homologation to give 6, chloride displacement to afford 7 and acidic hydrolysis to give 4. Amide formation between 4 and the carboxylic acid component then affords 3 directly.
Scheme 2. Synthesis of Azide 4
Reagents: a . NaN3 b . CHCl2Li, ZnCl2, c . LiN(TMS)2, d. 4M HCl, dioxane
Reduction of azide 3 to amine 8 may be accomplished by hydrogenation over precious metal catalysts. The preferred catalyst for this transformation is Pearlman's catalyst (palladium hydroxide on carbon). The amine is typically isolated as the hydrochloride salt. Isolation of 8 as the free base typically results in lowered yields. Salts of 8 which may confer superior physical properties may be preferred over the hydrochloride salt.
Formamidination of amine 8 may be accomplished using cyanamide. Due to the low reactivity of amine 8,
however, the preferred method for this transformation is reaction with 4-dimethylaminopyridine (DMAP) and
aminoiminomethanesulfonic acid (AMSA, prepared by the method of Kim, et. al., Tetrahedron Lett . 1988, 29, 3183-6). This affords guanidine 9, which is isolated as the bisulfite or hydrochloride salt.
Cleavage of pinanediol ester 9 may be accomplished using anhydrous boron trichloride according to the procedure of Matteson and Ray (J. Am . Chem . Soc . 1980, 102, 7588). This method, however, is strongly Lewis acidic and leads to partial destruction of the
substrate. The preferred method for water soluble boronic acids is a transesterification reaction that is run in the presence of excess phenylboronic acid. The free boronic acid 10 may then be isolated using cation exchange chromatography.
The isothiouronium functionalized analogs 11/12 are prepared from bromide 2 according to the procedure of Kettner and Shenvi (EP 0293881 A2).
Inhibitors containing a sulfonamide in place of a carboxamide are prepared from either 1 or 4 by reaction with a sulfonyl chloride in the presence of a hindered amine (Scheme 3). The product sulfonamide 13 is then converted to the guanidinium 14 or isothiouronium 15 in the same manner as the corresponding carboxamides.
Scheme 3. Synthesis of Sulfonamides
Inhibitors containing the borolysine moiety are prepared analogously to those containing boroarginine according to Kettner and Shenvi (EP 0293881 A2).
Novel biaryls synthesized in this invention are prepared through palladium catalyzed coupling of an appropriate arylmetal species to the aryl halide of choice using the methods described in Negishi, et. al., Org. Synth . 1987, 66, 61-14 , and references cited within.
EXAMPLE 1: N1-(4-Phenylbenzoyl)boroarginine (+)- Pinanediol, Bisulfite
Part A: ( +)-Pinanediol 4-bromo-1(R) -(4-phenylbenzoyl) aminobutane-1-boronate. To a solution of (+)- pinanediol 4-bromo-1 (R)-aminobutane-1-boronate
hydrochloride (5.00 g, 13.6 mmol) in dichloromethane (50 mL) at 0 °C was added 4-phenylbenzoyl chloride (4.97 g, 22.9 mmol) followed by N-methylmorpholine (4 mL, 36 mmol). After 1 hour, the cooling bath was removed and the mixture stirred at room temperature for 2 hours. The mixture was then diluted with ethyl acetate and washed with 0.1 M hydrochloric acid, saturated sodium bicarbonate and saturated sodium chloride. The organic phase was dried over anhydrous magnesium sulfate, filtered and the filtrate concentrated in vacuo to afford 3.37 g (48%) of the desired amide, mass spectrum: (M+H)+ = 510/512; 1H ΝMR (300 MHz, CDCI3) δ7.9 (2H, d, J
= 8.3), 7.84 (1H, bs), 7.6 (2H, d, J = 8.3), 7.44 (5H, m), 4.37 (1H, m) , 3.41 (1H, t, J = 6.9), 2.0 (10H, m) 1.49 (3H, s), 1.38 (1H, m) , 1.29 (3H, s) , 0.91 (3H, s). Part B: ( +) -Pinanediol 4-azido-1 (R) -(4-phenylbenzoyl) aminobutane-1-boronate. To a solution of (+)- pinanediol 4-bromo-1 (R)-(4-phenylbenzoyl) aminobutane-1- boronate (3.37 g, 6.60 mmol) in dimethylformamide (6 mL) was added sodium azide (547 mg, 8.41 mmol). The
resulting mixture was heated at 70 °C for 2 hours, cooled to room temperature, and diluted with ethyl acetate. The mixture was then washed with water, saturated sodium chloride and dried over anhydrous magnesium sulfate. Filtration, followed by
concentration of the filtrate in vacuo gave 3.04 g (97%) of the desired azide, mass spectrum: (M+H) + = 473; 1H ΝMR (300 MHz, CDCI3) δ7.89 (2H, d, J = 8.3), 7.75 (1H, bs), 7.3 (7H, m) , 4.32 (1H, m), 3.32 (1H, m), 2.0 (10H, m) 1.48 (3H, s) , 1.3 (4H, m) , 0.9 (3H, s).
Part C : N1- (4-Phenylbenzoyl) boroornithine ( +) - pinanediol, hydrochloride. To a solution of (+)- pinanediol 4-azido-1 (R)-(4-phenylbenzoyl)aminobutane-1- boronate (3.04 g, 6.44 mmol) in methanol (30 mL) was added Pearlman' s catalyst Pd(OH)2/C, 200 mg) and 1 M hydrochloric acid (6.5 mL, 6.5 mmol). The mixture was placed on a Parr apparatus and hydrogenated at 50 psi for 3 hours. The mixture was filtered using Celite™, washed with methanol and the filtrate concentrated in vacuo . The resulting amorphous solid was dissolved in water and washed with ether. The aqueous phase was then concentrated in vacuo and crystallized from ethyl acetate-hexanes, giving 1.52 g (49%) of the desired amine hydrochloride, mass spectrum: (M+H) + = 447; mp : 157-170 °C; 1H NMR (400 MHz, CDCl3/DMSO-d6) δ9.88 (1H, bs), 8.18, (2H, d, J = 8.3), 8.13 (3H, bs) , 7.68 (2H, d, J = 8.3), 7.61 (2H, d J = 7.0), 7.45 (2H, d, J = 7.0), 7.37 (1H, d, J = 7.30), 4.20 (1H, d, J = 6.3), 2.99 (1H, m), 2.87 (2H, m) , 2.31 (1H, m) , 2.13 (1H, m), 1 . 84 (7H, m) , 1 . 56 ( 1H, d, J = 10 . 0) , 1 . 42 (3H, s ) , 1 .29 (3H, s) , 0.89 (3H, s).
Part D : N1- (4-Phenylbenzoyl)boroarginine ( +) - pinanediol, bisulfite. To a solution of N1-(4- phenylbenzoyl)boroornithine (+)-pinanediol,
hydrochloride (80 mg, 0.17 mmol) in ethanol (2 mL) was added 4-dimethylaminopyridine (40 mg, 0.33 mmol). After 15 minutes, aminoiminomethanesulfonic acid (40 mg, 0.32 mmol) was added and the resulting mixture heated at reflux for 3 hours. After cooling to room temperature, the mixture was filtered and the filtrate concentrated in vacuo . The residue was dissolved in chloroform and washed with 0.1 M hydrochloric acid, water and dried over anhydrous magnesium sulfate. Filtration, followed by concentration of the filtrate in vacuo afforded 73 mg
(84%) of the desired guanidine, mass spectrum: (M+H)+ = 489; 1H NMR (400 MHz, CDCI3, 60 °C) δ9.48 (1H, bs) , 8.10
(2H, d, J = 8.1), 8.07 (1H, bs) , 7.75 (1H, bs) , 7.54
(2H, d, J = 8.3), 7.48 (2H, d, J = 7.0), 7.35 (3H, m) , 7.06 (4H, bs), 4.19 (1H, bd, J = 8.3), 3.1 (2H, m) , 2.84
(1H, m) , 2.29 (1H, m) , 2.12 (1H, m) , 1.96 (1H, m), 1.75
(6H, m) , 1.47 (1H, d, J = 10.2), 1.40 (3H, s) , 1.24 (3H, s) , 0.83 (3H, s). EXAMPLE 34: ( +) -Pinanediol 4-(Formamidino) thio-1 (R)-(4- phenylbenzoyl) aminobutane-1-boronate, Hydrobromide
( +) -Pinanediol 4-(formamidino)thio-1(R) - (A- phenylbenzoyl)aminobutane-1-boronate, hydrobromide. To a solution of (+)-pinanediol 4-bromo-1 (R)-(4-phenyl- benzoyl) aminobutane-1-boronate (200 mg, 0.392 mmol) in methanol (3 mL) was added thiourea (120 mg, 1.58 mmol). The reaction was stirred at room temperature for 3 days. The mixture was concentrated in vacuo, the residue dissolved in water and washed with ether. Concentration of the aqueous portion afforded 80 mg (35%) of the desired isothiourea, mass spectrum: (M+H)+ = 506; 1H NMR (300 MHz, CDCI3) δ8.15 (2H, d, J = 8.4), 7.61 (2H, d, J
= 8.4), 7.52 (2H, m), 7.38 (3H, m), 6.47 (1H, bs), 4.23 (1H, dd, J = 6.6, 1.9), 3.24 (1H, m), 3.14, (1H, m),
2.96, (1H, m), 2.32 (1H, m), 2.15 (1H, m), 1.99 (1H, m), 1.78 (6H, m), 1.48 (1H, d, J = 10.1), 1.42 (3H, s) , 1.27 (3H, s) , 0.86 (3H, s). The compounds listed in Tables 1-12 can be prepared using the above examples.
A: MS (M+H)+ = 489; 1H NMR (400 MHz, CDCl3, 60 °C)
9.48 (1H, bs), 8.10 (2 H, d, J = 8.1), 8.07 (1 H, bs), 7.75 (1 H, bs) , 7.54 (2 H, d, J = 8.3), 7.48 (2 H, d, J = 7.0), 7.35 (3 H, m) , 7.06 (4 H, bs) , 4.19 (1 H, bd, J = 8.3), 3.1 (2 H, m), 2.84 (1 H, m), 2.29 (1 H, m) , 2.12 (1 H, m) , 1.96 (1 H, m), 1.75 (6 H, m), 1.47 (1 H, d, J = 10.2), 1.40 (3 H, s) , 1.24 (3 H, s) , 0.83 (3 H, s).
B: MS (DCI - NH3) , 505 (M + H)
C: MS (M+H) 490
D: MS (M+H)+ = 506; 1H NMR (300 MHz, CDCl3) 8.15 (2 H, d, J = 8.4), 7.61 (2 H, d, J = 8.4), 7.52 (2 H, m), 7.38 (3 H, m), 6.47 (1 H, bs) , 4.23 (1 H, dd, J = 6.6, 1.9), 3.24 (1 H, m) , 3.14, (1 H, m) , 2.96, (1 H, m) , 2.32 (1 H, m), 2.15 (1 H, m), 1.99 (1 H, m), 1.78 (6 H, m), 1.48 (1 H, d, J = 10.1), 1.42 (3 H, s) , 1.27 (3 H, s) , 0.86 (3 H, s).
E: mp 145-150 °C.
F: MS (DCI - NH3) , 522 (M + H)+.
G: HRMS (DCI - NH3), Calc: 534.2597, Found: 534.2609. H: HRMS (DCI - NH3), Calc: 534.2597, Found: 534.2605.
I: HRMS (DCI - NH3), Calc: 534.2597, Found: 534.2609.
J: [a]D = -14.85° (c = 0.606, MeOH) ; 1H NMR (300 MHz, DMSO - d6) 10.07 (br s, 1 H) , 10.05 (br s, 1 H), 8.96 (4 H, br s), 8.08 (1 H, s) , 7.71 (1 H, dd, J = 8.1,
1.1), 7.61 (1 H, d, J = 7.7), 7.30 - 7.50 (6 H, m) , 5.18 (2 H, s), 4.08 (1 H, br d), 3.08 - 3.25 (2 H, m), 2.50 - 2.65 (1 H, m), 2.15 - 2.30 (1 H, m), 1.97 - 2.10 (1 H, m), 1.40 - 1.90 (8 H, m), 1.31 (3 H, s), 1.24 (3 H, s), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1734, 1646, 1578, 1550, 1440, 1222, 1058 cm-1; MS (Cl - NH3), m/e (%) 537.2 (10.2, M + H - H2NCN)+) ,
429.0 (42.8), 277.0 (100); Anal. Calcd for
C30H40BBrN4O5S: C, 54.64; H, 6.11; N, 8.50; B, 1.64. Found: C, 54.52; H, 6.16; N, 8.45; B, 1.60.
K: [a]D = -15.07° (c = 0.604, MeOH) ; 1H NMR (300 MHz, DMSO - d6) 9.98 (1 H, br s), 8.96 (4 H, br s), 7.93 (1 H, narrow m), 7.80 (1 H, app d), 7.64 (1 H, m), 7.56 (1 H, app t), 7.25 - 7.42 (5 H, m), 5.13 (2 H, s), 4.11 (1 H, dd, J = 8.3, 1.7), 3.30 (3 H, s), 3.10 - 3.25 (2 H, m), 2.57 - 2.68 (1 H, m), 2.15 - 2.30 (1 H, m), 1.97 - 2.10 (1 H, m), 1.48 - 1.90 (7 H, m), 1.44 (1 H, d, J = 9.9), 1.31 (3 H, s), 1.24 (3 H, s), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1710,
1647, 1159 cm-1; MS (Cl - NH3), m/e (%) 593.2 (1.2, (M + H)+), 568.3 (22, (M + NH4 - H2NCN)+), 551.3 (100, (M + H - H2NCN)+); Anal. Calcd for C31H42BBrN4O5S : C, 55.29; H, 6.29; N, 8.32; B, 1.61. Found: C, 55.15; H, 6.21; N, 8.22; B, 1.47.
1: [a]D = -14.12° (c = 0.602, MeOH); 1H NMR (300 MHz, DMSO - d6) 10.09 (1 H, br s), 8.98 (4 H, br s), 7.90 (2 H, d, J = 8.3), 7.42 (2 H, d, J = 8.3), 4.06 (1 H, d, J = 7.0), 3.15 - 3.20 (2 H, m), 2.70 (2 H, q, J = 7.7), 2.54 (1 H, m), 2.18 - 2.28 (1 H, m), 1.98 - 2.08 (1 H, m), 1.44 - 1.84 (8 H, m), 1.30 (3 H, s), 1.24 (3 H, s), 1.20 (3 H, t, J = 7.7), 0.84 (3 H, s); IR (KBr) 2600 - 3700 (br), 1646, 1614, 1598, 1570, 1500, 1123 cm-1; MS (DCI - NH3), m/e (%) 458 (100, (M
+ H)+); Anal. Calcd for C24H37BBrN3O3S : C, 53.54; H, 6.93; N, 7.81; B, 2.01. Found: C, 53.75; H, 6.98; N, 7.74; B, 1.97. M: [a]D = -14.21° (c = 0.556, MeOH); 1H NMR (300 MHz, DMSO - d6) 10.06 (1 H, br s) , 8.95 (4 H, br s) , 7.88 (2 H, d, J = 8.1), 7.40 (2 H, d, J = 8.1), 4.06 (1 H, dd, J = 1.7, 8.3), 3.14 - 3.17 (2 H, m), 2.65 (2 H, t, J = 7.5), 2.50 - 2.60 (1 H, m) , 2.18 - 2.28 (1 H, m) , 1.98 - 2.08 (1 H, m), 1.45 - 1.84 (10 H, m), 1.30 (3 H, s), 1.24 (3 H, s) , 0.89 (3 H, t, J = 7.3), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br) , 1646, 1614, 1598, 1570, 1500, 1446, 1236, 1124, 1082 cm-1; MS (Cl - NH3), m/e (%) 472.2 (13.5, (M + H)+), 430.2 (100, (M + H - H2NCN)+), 278.0 (61.9); Anal. Calcd for
C25H39BBrN3O3S: C, 54.36; H, 7.12; N, 7.61; B, 1.96. Found: C, 54.50; H, 7.18; N, 7.83; B, 1.73.
N: [a]D = -13.79° (c = 0.602, MeOH); 1H NMR (300 MHz, DMSO - d6) 10.03 (1 H, br s) , 8.94 (4 H, br s) , 7.89 (2 H, d, J = 8.3), 7.45 (2 H, d, J = 8.3), 4.06 (1 H, br d) , 3.10 - 3.23 (2 H, m), 2.90 - 3.05 (1 H, m) , 2.50 - 2.60 (1 H, m) , 2.15 - 2.30 (1 H, m), 1.95 - 2.08 (1 H, m), 1.42 - 1.89 (8 H, m), 1.30 (3 H, s) , 1.24 (3 H, s), 1.23 (6 H, d, J = 7.0), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1646, 1613, 1598, 1123 cm- 1 ; MS (DCI - NH3), m/e (%) 472 (100, (M + H)+), 430 (37, (M + H - H2NCN)+); Anal. Calcd for
C25H39BBrN3O3S: C, 54.36; H, 7.12; N, 7.61; B, 1.96. Found: C, 54.64; H, 7.17; N, 7.50; B, 1.74.
0: [a]D = -13.19° (c = 0.364, MeOH); 1H NMR (300 MHz, DMSO - d6) 10.03 (1 H, br s) , 8.93 (4 H, br s) , 7.88 (2 H, d, J = 8.5), 7.40 (2 H, d, J = 8.5), 4.06 (1 H, br d, J = 6.6), 3.15 - 3.20 (2 H, m) , 2.67 (2 H, t, J
= 7.7), 2.50 - 2.60 (1 H, m), 2.18 - 2.28 (1 H, m), 1.95 - 2.08 (1 H, m), 1.24 - 1.84 (10 H, m), 1.23 - 1.35 (2 H, m), 1.30 (3 H, s), 1.24 (3 H, s), 0.90 (3 H, t, J = 7.3), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1646, 1614, 1598, 1500, 1123 cm-1; MS (Cl -
NH3), m/e (%) 486.2 (3.3, (M + H)+), 444.2 (87.1, (M + H - H2NCN)+), 292.0 (100); Anal. Calcd for
C26H41BBrN3O3S: C, 55.13; H, 7.30; N, 7.42; B, 1.91. Found: C, 54.99; H, 7.22; N, 7.29; B, 2.07.
P: [a]D = -12.71° (c = 0.598, MeOH); 1H NMR (300 MHz, DMSO - d6) 10.05 (1 H, br s), 8.95 (4 H, br s), 7.90 (2 H, d, J = 8.6), 7.59 (2 H, d, J = 8.6), 4.06 (1 H, br d), 3.10 - 3.23 (2 H, m), 2.50 - 2.62 (1 H, m), 2.16 - 2.30 (1 H, m), 1.96 - 2.08 (1 H, m), 1.42 -
1.90 (8 H, m), 1.31 (9 H, s), 1.30 (3 H, s), 1.24 (3 H, s), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1646, 1613, 1597, 1498, 1123 cm-1; MS (DCI - NH3), m/e (%) 486 (100, (M + H)+), 444 (16, (M + H - H2NCN)+); Anal. Calcd for C26H41BBrN3O3S : C, 55.13; H, 7.30; N, 7.42; B, 1.91. Found: C, 55.09; H, 7.45; N, 7.40; B, 1.67.
Q:1H NMR (300 MHz, DMSO - d6) §10.06 (1 H, br s), 8.95 (4 H, br s), 7.88 (2 H, d, J = 8.5), 7.40 (2 H, d, J = 8.5), 4.06 (1 H, br d, J = 6.6), 3.10 - 3.23 (2 H, m), 2.66 (2 H, t, J = 7.7), 2.50 - 2.60 (1 H, m), 2.15 - 2.30 (1 H, m), 1.95 - 2.08 (1 H, m), 1.40 - 1.90 (10 H, m), 1.20 - 1.38 (12 H, m), 0.80 - 0.90 (6 H, m); IR (KBr) 2500 - 3700 (br), 1646, 1614, 1598,
1500, 1124 cm-1; MS (DCI - NH3), m/e (%) 514 (100, (M + H)+), 472 (16, (M + H - H2NCN)+); Anal. Calcd for C28H45BBrN3O3S: C, 56.57; H, 7.63; N, 7.07; B, 1.82. Found: C, 56.19; H, 7.53; N, 6.97; B, 1.99.
R: [a]D = -11.70° (c = 0.530, MeOH); 1H NMR (300 MHz, DMSO - d6) d10.05 (1 H, br s) , 8.83 - 9.13 (4 H, br d) , 7.88 (2 H, d, J = 8.3), 7.43 (2 H, d, J = 8.3), 4.06 (1 H, br d) , 3.05 - 3.25 (2 H, m), 2.45 - 2.67 (2 H, m), 2.13 - 2.30 (1 H, m) , 1.94 - 2.10 (1 H, m), 1.30 - 1.90 (18 H, m), 1.30 (3 H, s) , 1.24 (3 H, s), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br) , 1646, 1613, 1598, 1500, 1448, 1122 cm-1; MS (DCI - NH3) , m/e (%) 512 (100, (M + H)+), 470 (40, (M + H - H2NCN)+); Anal. Calcd for C28H43BBrN3O3S : C, 56.77; H, 7.32; N, 7.09; B, 1.82. Found: C, 56.49; H, 7.38; N, 6.96; B, 1.75.
S: HRMS (DCI - NH3), Calc: 577.3019, Found: 577.3025. T: [a]D = -8.31° (c = 0.614, MeOH); 1H NMR (300 MHz, DMSO - d6) d9.98 (1 H, br s) , 8.95 (4 H, br s) , 7.93 (2 H, d, J = 8.8), 7.11 (2 H, d, J = 8.8), 4.00 - 4.10 (3 H, m) , 3.10 - 3.23 (2 H, m) , 2.50 - 2.60 (1 H, m), 2.15 - 2.30 (1 H, m) , 1.95 - 2.08 (1 H, m), 1.37 - 1.90 (12 H, m), 1.29 (3 H, s) , 1.24 (3 H, s) , 0.94 (3 H, t, J = 7.4), 0.84 (3 H, s); IR (KBr) 2500 - 3700 (br), 1646, 1608, 1498, 1262, 1124 cm-1; MS (DCI - NH3), m/e (%) 502 (100, (M + H)+), 460 (28, (M + H - H2NCN)+); Anal. Calcd for C26H41BBrN3O4S : C, 53.62; H, 7.10; N, 7.21; B, 1.86. Found: C, 53.61; H, 7.09; N, 7.20; B, 1.78.
U: HRMS (DCI - NH3), Calc: 513.2707, Found: 513.2702. V: HRMS (DCI - NH3), Calc: 555.3165, Found: 555.3176. W: HRMS (DCI - NH3), Calc: 579.2812, Found: 579.2801.
X: HRMS (DCI - NH3), Calc: 450.2962, Found: 450.2958. Y: HRMS (DCI - NH3), Calc: 640.3016, Found: 640.3022.
Z: [a]D = -8.80° (c = 0.602, MeOH) ; 1H NMR (300 MHz, DMSO - d6) 10.03 (1 H, br s), 9.25 (1 H, br s), 8.96
(4 H, br s) , 7.92 (1 H, d, J = 1.5), 7.72 (1 H, dd, J = 8.1, 1.5), 7.25 - 7.50 (6 H, m), 5.17 (2 H, s), 4.08 (1 H, dd, J = 8.1, 1.5), 3.08 - 3.27 (2 H, m), 2.65 (2 H, br t), 2.50 - 2.60 (1 H, m), 2.15 - 2.30
(1 H, m), 1.95 - 2.08 (1 H, m), 1.40 - 1.90 (10 H, m), 1.30 (3 H, s), 1.24 (3 H, s), 1.15 - 1.38 (2 H, m, buried underneath methyl absorptions), 0.77 - 0.95
(6 H, m); IR (KBr) 2500 - 3700 (br), 1704, 1646, 1572, 1539, 1453, 1234, 1123, 1056 cm-1; MS (Cl - NH3), m/e (%) 593.2 (1.3, (M + H - H2NCN)+), 485.2
(42.7), 333.0 (100); Anal. Calcd for C34H48BBrN4O5S: C, 57.07; H, 6.76; N, 7.83; B, 1.51. Found: C,
57.17; H, 6.84; N, 7.76; B, 1.41.
AA: 1H NMR (300 MHz, DMSO - d6) §9.98 (1 H, br s), 8.98 (4 H, br s), 7.77 - 7.92 (2 H, m), 7.08 - 7.55 (6 H, m), 4.90 - 5.30 (2 H, m), 4.09 (1 H, br d), 3.04 - 3.35 (5 H, m), 2.35 - 2.65 (3 H, m), 2.15 - 2.30 (1 H, m), 1.97- 2.10 (1 H, m), 1.37- 1.93 (10 H, m), 1.31 (3 H, s), 1.24 (3 H, s), 1.10 - 1.37 (2 H, m, buried underneath methyl absorptions), 0.72 - 0.93 (6 H, m); MS (Cl - NH3), m/e (%) 649.4 (1.9, (M +
H)+), 624.4 (31, (M + NH4 - H2NCN)+) , 607.2 (100, (M + H - H2NCN)+), 455.0 (39), 444.0 (29.8); Anal. Calcd for C35H50BBrN4O5S: C, 57.62; H, 6.91; N, 7.68; B, 1.48. Found:
C, 57.37; H, 6.86; N, 7.64; B, 1.40.
BB: HRMS (DCI - NH3), Calc: 520.2805, Found: 520.2796.
CC: HRMS (DCI - NH3), Calc: 560.2390, Found: 560.2407. DD: HRMS (DCI - NH3), Calc: 596.2060, Found: 596.2055.
EE: HRMS (DCI - NH3), Calc: 546.2597, Found: 546.2604.
FF: HRMS (DCI - NH3), Calc: 534.2597, Found: 534.2609. GG: HRMS (DCI - NH3), Calc: 532.2441, Found: 532.2445.
HH: HRMS (DCI - NH3), Calc : 532.2441, Found: 532.2452.
II: HRMS (DCI - NH3), Calc: 480.2493, Found: 480.2492.
JJ: HRMS (DCI - NH3), Calc: 496.2441, Found: 496.2449.
KK: HRMS (DCI - NH3), Calc: 507.2601, Found: 507.2592. LL: HRMS (DCI - NH3), Calc: 537.2667, Found: 537.2685.
MM: HRMS (DCI - NH3), Calc: 498.2233, Found: 498.2231.
NN: HRMS (DCI - NH3), Calc: 481.2445, Found: 481.2442.
OO: HRMS (DCI - NH3), Calc: 557.2758, Found: 557.2754.
PP: HRMS (DCI - NH3), Calc: 5481.2445, Found: 481.2440. QQ: HRMS (NH3) - CI/DEP), Calc: 503.3193, Found: 503.3199.
RR: HRMS (DCI-NH3), Calc: 605.333; Found: 605.3325.
Utility
The compounds of formula (I) are useful as inhibitors of trypsin-like enzymes, notably human thrombin,
plasma kallikrein and plasmin. Because of their
inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological
reactions catalyzed by the aforesaid enzymes such as blood coagulation and inflammation.
As an illustration of the above, the biological activity of compounds of the present invention is demonstrated by their in vitro inhibition of
synthetic substrate hydrolysis by human thrombin S- 2238 Chromogenic Assay (IC50). The synthetic
substrate H-D-Phe-Pip-Arg-pNA (S-2238, Kabi) is cleaved by thrombin, liberating the p-nitroanalide group which absorbs light at 405 nm. Enzyme activity is measured in both the presence and absence of inhibitor. A decrease in absorbance at 405 nm in the presence of inhibitor is indicative of thrombin inhibition.
A mixture of 10 μL human thrombin (Enzyme Research Laboratories, Inc.) at an activity of approximately 7 units/mL, 10 μL of the inhibitor (normally at a concentration of 10-3 M or less), and 160 μL buffer (0.15 M NaCl, 10 mM HEPES, 10 mM Tris, 1 g/L PEG 8,000, pH 7.4) are incubated for 10 minutes at room temperature. To this mixture is added 20 μL of the synthetic substrate S-2238 at a concentration of 1 mM and the reaction allowed to occur for 10 minutes, after which absorbance at 405 nm is determined.
Using the methodology described above,
representative compounds of this invention were evaluated and found to exhibit an IC50 of less than 1 mM, thereby confirming the utility of the compounds of the invention as effective thrombin inhibitors.
Since the compounds of formula (I) have anti- thrombogenic properties, they may be employed when an anti-thrombogenic agent is indicated, such as for control of the coagulation or the fibrinolysis system in mammals or they may be added to blood for the purpose of preventing coagulation or the blood due to
contact with blood collecting or distribution containers, tubing or apparatus.
Generally, these compounds may be administered orally or parenterally to a host to obtain an anti- thrombogenic effect. The dosage of the active compound depends on the mammalian species, body weight, age, and mode of administration as will be obvious to one skilled in the art. In the case of large mammals such as humans, the compounds may be administered alone or in combination with
pharmaceutical carriers or diluents at a dose of from 0.02 to 15 mg/Kg to obtain the anti-thrombogenic effect, and may be given as a single dose or in divided doses or as a sustained release formulation.
Pharmaceutical carriers or diluents are well known and include sugars, starches and water, which may be used to make tablets, capsules, injectable solutions or the like which can serve as suitable dosage forms for administration of the compounds of this
invention. Remington's Pharmaceutical Sciences, A.
Osol, is a standard reference text which discloses suitable pharmaceutical carriers and dosage forms . The disclosure of this text is hereby incorporated by reference for a more complete teaching of suitable dosage forms for administration of the compounds of this invention.
Claims
1. A compound of formula (I)
R1-Z-CCHR2-BY1Y2
(I) wherein
Y1 and Y2 are independently
a) -OH
b) -F,
c) - NR3R4, or
d) C1-C8- alkoxy;
Y1 and Y2 when taken together can form
a) a cyclic boron ester where said chain or
ring contains from 2 to 20 carbon atoms and, optionally, a heteroatom which can be N, S, or O,
b) a divalent cyclic boro amide where said chain or ring contains from 2 t 20 carbon atoms, c) a cyclic boro amide-ester where said chain or ring contains from 2 to 20 carbon atoms;
Z is
a) -(CH2)mCONR8-,
b) -(CH2)mCSNR8-,
c) -(CH2)mSO2NR8-,
d) -(CH2)mCO2-,
e) -(CH2)mC(S)O-, or
f) -(CH2)mSO2O-;
R1 is
a) - (CH2)p-aryl, wherein aryl is phenyl, naphthyl or biphenyl substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), CN, C1-C10- alkyl, C3-C8-cycloalkyl, C2-C10-alkenyl, C2--C10-alkynyl, -R8, -OR8, methylenedioxy, -NO2, -CF3, -S(O)rR7, NR8R9, -COR8, -CO2R8, -CONR8R9, NR8COR9, NR8CO2R9, 
b) heteroaryl, wherein heteroaryl is an
unsubstituted or monosubstituted or
disubstituted
i) 5- or 6-membered aromatic ring, which
contains from 1 to 3 heteroatoms selected from the group consisting of O, N, and S, ii) quinolinyl,
iii) isoquinolinyl,
iv) benzopyranyl,
v) benzothiophenyl,
vi) benzofuranyl,
vii) 5,6,7,8-tetrahydroquinolinyl
viii) 5,6,7,8-tetrahydroisoquinolinyl and wherein the subtitutents are members selected from the group consisting of halo (F, Cl, Br, I, -CN, C1-C10-alkyl, C3-C8-cycloalkyl, C2-C10- alkenyl, C2-C10-alkynyl, -R8, OR8, NO2, -CF3,
-S(O)rR7, NR8R9, -COR8, -CONR8R9, NR8COR9,
NR8CO2R9,
R2 is
a) -(CH2) n-NHC (NH)NH2, b) -(CH2) n-NHC (NH)NHCOCH3, c) -(CH2)n-SC(NH)NH2, e) -(CH2)n-SC(NH)2,or f) - (CH) n-NH (2-pyridyl);
R3 is H, phenyl or C1-C4-alkyl; R4 is H, or phenylsulfonyl;
R5 and R6 are hydrogen or when taken together form a six membered aromatic ring optionally substituted with one, two or three substituents selected from the group consisting of halo (F, Cl, Br, I), -CN, C1-C10- alkyl, C3-C8-cycloalkyl, C2-C10-alkenyl, C2-C10- alkynyl, -OR8, -NO2, -CF3, -S(O)rR7, -NR8R9, -COR8, -COR2R8, -CONR8R9, phenyl, benzyl, phenylethyl;
R7 is
a) phenyl,
b) C1-C4-alkyl,
c) C1-C4-alkoxy, or
d) -CF3;
R8 and R9 are independently
a) H,
c) C3-C7-Cycloalkyl,
d) C1-C8-alkyl;
R10 and R11 are independently
a) halo (F, Cl, Br, I),
b) -CN,
c) C1-C10-alkyl,
d) C3-C8-cycloalkyl,
e) C2-C10-alkenyl,
f) C2-C10-alkynyl,
g) -OR8,
h) NO2,
i) -CF3,
j) -S(O)rR7,
k) -NR8R9,
l) -COR9,
m) -CO2R8, or
n) -CONR8R9; R12 is
a) H,
b) C1-C4-alkyl,
c) phenyl
d) benzyl,
e) -COR7
f) -SO2R7
m is 0 to 6;
n is 3 or 4,
p is 0 to 2,
r is 0 to 2,
t is 1 to 5
E is -CO-, -SO2-,-CH2- or a single bond,
F is -CO-, and
pharmaceutically acceptable salts thereof.
2. A compound of Claim 1 wherein:
Rl is phenyl containing 1-3
substituents selected from the series halo (F, CL, Br, I), Cl-ClO-alkyl, C3-C8-cycloalkyl, C2-C10- alkenyl, C2-C10-alkynyl, -R8, -OR8, -NO2, -CF3, -S(O)rR7, -NR8R9, -COR8, -CO2R8, CONR8R9, NR8COR9' and 
; and
R2 is
a) -(CH2)3-NHC(NH)NH2, or
b) -(CH2)3-SC(NH)NH2.
3. A compound of Claim 2 wherein Z is - (CH2)mCONR8-.
4. A compound of Claim 3 selected from the group
consisting of
N1-(4-phenylbenzoyl)-(R)-boroarganine, hydrochloride, N1-(3-phenoxybenzoyl)-(R)-boroarganine, hydrochloride, N1-(1-fluorenonyl)-(R)-boroarginine, hydrochloride,N1-(4-[butyl]benzoyl)-(R)-boroarginine, hydrochloride, N1-(2-benzoylbenzoyl)-R-boroarginine, hydrochloride, N1-(5-phenyl-2-furol)-R-boroarginine, hydrochloride, N1-(3-[N-benzyloxycarbonyl-N-methylamino]-4-[1-butyl]- benzoyl)-(R)-boroarginine, hydrochloride,
N1-(2-phenyl-4-isoquinolyl)-(R)-boroarginine,
hydrochloride,
N1-(4-cyclohexylbenzoyl)-(R)-boroarginine, hydrochloride N1-(2-methyl-4-phenylbenzoyl)-(R)-boroarginine,
hydrochloride, or
5. A pharmaceutical composition comprising a
pharmaceutically suitable carrier and a
therapeutically effective amount of a compound of any one of claims 1 through 4.
6. A method of treating a physiological disorder in a warm blooded animal catalyzed by trypsin-like enzymes comprising administering to an animal in need of such treatment an effective amount of a compound of any one of claims 1 through 4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU64487/94A AU6448794A (en) | 1993-03-24 | 1994-03-23 | Boronic acid and ester inhibitors of thrombin |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3637793A | 1993-03-24 | 1993-03-24 | |
| US08/036,377 | 1993-03-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1994021650A1 true WO1994021650A1 (en) | 1994-09-29 |
Family
ID=21888279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1994/002965 WO1994021650A1 (en) | 1993-03-24 | 1994-03-23 | Boronic acid and ester inhibitors of thrombin |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU6448794A (en) |
| WO (1) | WO1994021650A1 (en) |
| ZA (1) | ZA942082B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724446A1 (en) * | 1993-10-07 | 1996-08-07 | The Du Pont Merck Pharmaceutical Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| FR2745288A1 (en) * | 1996-02-27 | 1997-08-29 | Adir | NOVEL BORONIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP0810858A2 (en) * | 1994-12-27 | 1997-12-10 | The Du Pont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
| JP2006503903A (en) * | 2002-09-09 | 2006-02-02 | トライジェン・リミテッド | Boronic acid polyvalent metal salt for the treatment of thrombosis |
| US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0293881A2 (en) * | 1987-06-05 | 1988-12-07 | The Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0471651A2 (en) * | 1990-08-13 | 1992-02-19 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
| WO1992007869A1 (en) * | 1990-11-06 | 1992-05-14 | Thrombosis Research Institute | Inhibitors and substrates of thrombin |
-
1994
- 1994-03-23 AU AU64487/94A patent/AU6448794A/en not_active Abandoned
- 1994-03-23 WO PCT/US1994/002965 patent/WO1994021650A1/en active Application Filing
- 1994-03-24 ZA ZA942082A patent/ZA942082B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0293881A2 (en) * | 1987-06-05 | 1988-12-07 | The Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0471651A2 (en) * | 1990-08-13 | 1992-02-19 | Sandoz Ltd. | Peptide boronic acid derivatives having protease inhibiting activity |
| WO1992007869A1 (en) * | 1990-11-06 | 1992-05-14 | Thrombosis Research Institute | Inhibitors and substrates of thrombin |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0724446A1 (en) * | 1993-10-07 | 1996-08-07 | The Du Pont Merck Pharmaceutical Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| EP0724446A4 (en) * | 1993-10-07 | 1998-01-07 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| EP0810858A2 (en) * | 1994-12-27 | 1997-12-10 | The Du Pont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
| EP0810858A4 (en) * | 1994-12-27 | 2000-11-15 | Du Pont Pharm Co | Boronic acid and ester inhibitors of thrombin |
| FR2745288A1 (en) * | 1996-02-27 | 1997-08-29 | Adir | NOVEL BORONIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP0792883A1 (en) * | 1996-02-27 | 1997-09-03 | Adir Et Compagnie | Novel derivates of boronic acid, process for their preparation and pharmaceutical compositions containing them |
| CN1076353C (en) * | 1996-02-27 | 2001-12-19 | 阿迪尔公司 | New compounds derived from boronic acid, process for their preparation and pharmaceutical compositions containing them |
| JP2006503903A (en) * | 2002-09-09 | 2006-02-02 | トライジェン・リミテッド | Boronic acid polyvalent metal salt for the treatment of thrombosis |
| US7112572B2 (en) | 2002-09-09 | 2006-09-26 | Trigen Limited | Multivalent metal salts of boronic acids |
| US7371729B2 (en) | 2002-09-09 | 2008-05-13 | Trigen Limited | Boronic acid salts useful in parenteral formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6448794A (en) | 1994-10-11 |
| ZA942082B (en) | 1995-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5288707A (en) | Borolysine peptidomimetics | |
| US5858979A (en) | Inhibitors and substrates of thrombin | |
| EP1050540B1 (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
| US5462928A (en) | Inhibitors of dipeptidyl-aminopeptidase type IV | |
| RU2075481C1 (en) | Derivatives of boron-containing peptides and pharmaceutical composition exhibiting inhibiting activity to trypsin-like serine proteases | |
| EP0293881A2 (en) | Peptide boronic acid inhibitors of trypsin-like proteases | |
| JPH08511018A (en) | Novel peptide derivative | |
| WO1995009858A1 (en) | Dipeptide boronic acid inhibitors of trypsin-like enzymes | |
| RU2152953C1 (en) | Derivatives of dipeptide p-amidinobenzylamides with n-terminal sulfonyl residues and their salts with physiologically acceptable acids | |
| WO1995009859A1 (en) | Boropeptide inhibitors of thrombin which contain a substituted pyrrolidine ring | |
| US5639739A (en) | Imidazole containing aminoboronic acids | |
| US5462964A (en) | Dipeptide boronic acid inhibitors of trypsin-like enzymes | |
| AU707059B2 (en) | Serine protease inhibitors | |
| WO1994021650A1 (en) | Boronic acid and ester inhibitors of thrombin | |
| US6235707B1 (en) | Anticoagulant peptidyl-arginine aldehyde derivatives | |
| EP0846120A1 (en) | Low molecular weight bicyclic-area type thrombin inhibitors | |
| US5731439A (en) | Piperidine containing aminobornic acids | |
| US5648338A (en) | Inhibitors and substrates of thrombin | |
| EP0865445B1 (en) | 3-aminoethyl-n-amidino-2,5-dihydropyrrole derivatives having arginine mimetic properties | |
| US5856309A (en) | Amidinopyrroline derivatives, processes for their production and pharmaceutical agents containing these compounds | |
| US6387881B1 (en) | Inhibitors and substrates of thrombin | |
| JPH0892268A (en) | New phosphoric acid derivative | |
| NO300504B1 (en) | Compound and therapeutic composition comprising this |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP NZ |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |